Cargando…

P543: CONSECUTIVE DAY DOSING OF HIGH-DOSE CYTARABINE CONSOLIDATION OVER 3 DAYS IS FEASIBLE IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA

Detalles Bibliográficos
Autores principales:	Nedumannil, Rithin, Batterham, Emily, Wei, Andrew, Bajel, Ashish
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428938/ http://dx.doi.org/10.1097/01.HS9.0000969080.96146.ca

Ejemplares similares

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

Safety and Feasibility of Outpatient High Dose Cytarabine for Acute Myeloid Leukemia in the Brazilian Amazon
por: Rodrigues, Amanda Lopes Maia, et al.
Publicado: (2020)

Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia
por: Azevedo, M.C., et al.
Publicado: (2014)

Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis
por: Wu, Di, et al.
Publicado: (2017)

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
por: Jaramillo, S, et al.
Publicado: (2017)

Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience
por: Bashir, Yasir, et al.
Publicado: (2015)

Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia
por: Canaani, Jonathan, et al.
Publicado: (2020)

Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia
por: Wei, Hui, et al.
Publicado: (2020)

A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia
por: Wu, Ziliang, et al.
Publicado: (2022)

Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study
por: Ye, Li, et al.
Publicado: (2021)

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
por: Galtier, Jean, et al.
Publicado: (2021)

The prognostic benefit from intermediate-dose cytarabine as consolidation therapy varies by cytogenetic subtype in t(8;21) acute myeloid leukemia: a retrospective cohort study
por: Chen, Guofeng, et al.
Publicado: (2022)

Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.
por: Mulder, P. O., et al.
Publicado: (1990)

Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia
por: Anders, Brandi, et al.
Publicado: (2017)

High-Dose Cytarabine in Acute Myeloid Leukemia Treatment: A Systematic Review and Meta-Analysis
por: Li, Wei, et al.
Publicado: (2014)

Extreme Thrombocytosis in Refractory ITP Post-Splenectomy With Associated Fatal Thromboembolism
por: Nedumannil, Rithin, et al.
Publicado: (2022)

Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study
por: Li, Xiaoyang, et al.
Publicado: (2019)

Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China
por: Wang, Ling, et al.
Publicado: (2016)

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
por: Rassidakis, George Z., et al.
Publicado: (2018)

Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
por: Ferrara, Felicetto
Publicado: (2020)

Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia
por: Smoljo, Tomislav, et al.
Publicado: (2023)

Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study
por: Wang, Li, et al.
Publicado: (2022)

High-dose cytarabine monotherapy is superior to standard-dose cytarabine- based multiagent sequential treatment cycle for consolidation treatment in adult (14-59 years) AML patients according to European Leukemia Net 2022 risk stratification
por: Wang, Xiaoyu, et al.
Publicado: (2023)

Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women
por: Stoffel, Nicole U., et al.
Publicado: (2020)

The prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high-dose cytarabine
por: Ahmad, Ebtesam I, et al.
Publicado: (2011)

Corneal Epithelial Microcysts due to High-Dose Cytarabine Administration in a Pediatric Acute Myeloid Leukemia Patient
por: Karapınar, Tuba Hilkay, et al.
Publicado: (2012)

Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists
por: Relias, Valerie, et al.
Publicado: (2020)

Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
por: Zucenka, Andrius, et al.
Publicado: (2021)

Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia
por: Tsai, Hui‐Jen, et al.
Publicado: (2021)

A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML
por: Schwarer, Anthony P., et al.
Publicado: (2018)

PB1838: TOXICITY AND OUTCOME OF HIGH DOSE CYTARABINE (18 G/M2) FOR AML CONSOLIDATION.
por: Lopes, L., et al.
Publicado: (2022)

Comparison of the 24 h Dietary Recall of Two Consecutive Days, Two Non-Consecutive Days, Three Consecutive Days, and Three Non-Consecutive Days for Estimating Dietary Intake of Chinese Adult
por: Huang, Kun, et al.
Publicado: (2022)

A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
por: Schliemann, Christoph, et al.
Publicado: (2016)

Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
por: Patzke, Ciera L., et al.
Publicado: (2020)

The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia
por: Fredly, Hanne, et al.
Publicado: (2013)

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
por: Wang, Amy Y., et al.
Publicado: (2018)

Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy
por: Shin, Seung-Hwan, et al.
Publicado: (2017)

Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study
por: van Eijkelenburg, Natasha K.A., et al.
Publicado: (2018)

Undetected Severe Fetal Myelosuppression following Administration of High-Dose Cytarabine for Acute Myeloid Leukemia: Is More Frequent Surveillance Necessary?
por: Parrott, Jessica, et al.
Publicado: (2017)

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
por: Cortes, Jorge E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ccs8ub2r51an0voft0u0js8j50